EP1534332A4 - Antibodies and uses thereof - Google Patents

Antibodies and uses thereof

Info

Publication number
EP1534332A4
EP1534332A4 EP03762258A EP03762258A EP1534332A4 EP 1534332 A4 EP1534332 A4 EP 1534332A4 EP 03762258 A EP03762258 A EP 03762258A EP 03762258 A EP03762258 A EP 03762258A EP 1534332 A4 EP1534332 A4 EP 1534332A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03762258A
Other languages
German (de)
French (fr)
Other versions
EP1534332A2 (en
Inventor
Avigdor Levanon
Rachel Ben-Levy
Daniel Plaksin
Esther Szanton
Yocheved Hagai
Mar-Chaim Hagit Hoch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savient Pharmaceuticals Inc
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of EP1534332A2 publication Critical patent/EP1534332A2/en
Publication of EP1534332A4 publication Critical patent/EP1534332A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
EP03762258A 2002-07-01 2003-06-30 Antibodies and uses thereof Withdrawn EP1534332A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US189032 1998-11-10
US18903202A 2002-07-01 2002-07-01
PCT/US2003/020602 WO2004003166A2 (en) 2002-07-01 2003-06-30 Antibodies and uses thereof

Publications (2)

Publication Number Publication Date
EP1534332A2 EP1534332A2 (en) 2005-06-01
EP1534332A4 true EP1534332A4 (en) 2006-11-22

Family

ID=29999594

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03762258A Withdrawn EP1534332A4 (en) 2002-07-01 2003-06-30 Antibodies and uses thereof

Country Status (12)

Country Link
EP (1) EP1534332A4 (en)
JP (1) JP2005536199A (en)
KR (1) KR20060011925A (en)
CN (1) CN1678347A (en)
AU (1) AU2003263764A1 (en)
BR (1) BR0312483A (en)
CA (1) CA2491363A1 (en)
IL (1) IL166063A0 (en)
MX (1) MXPA05000272A (en)
PL (1) PL374439A1 (en)
RU (1) RU2005101621A (en)
WO (1) WO2004003166A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (en) 2003-09-05 2005-03-06 Gentium Spa FORMATIONS FOR ANTITUMORAL ACTION.
KR20120085921A (en) 2004-05-11 2012-08-01 압제노믹스 코오페라티에프 유.에이. T-cell death-inducing epitopes
US20070298034A9 (en) * 2005-12-09 2007-12-27 Angela Widom Sulfotyrosine specific antibodies and uses therefor
CA2813413C (en) 2010-11-12 2018-03-06 Gentium S.P.A. Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd)
CA2838952C (en) 2011-06-13 2020-11-24 Stefan Bassarab Anti-psgl-1 antibodies and uses thereof
SG11201408481UA (en) 2012-06-22 2015-01-29 Gentium Spa Euglobulin-based method for determining the biological activity of defibrotide
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
KR101896751B1 (en) * 2015-12-01 2018-10-04 주식회사 엘지화학 Thermoplastic resin, method for preparing the resin and thermoplastic resin composition comprising the resin
MX2021000786A (en) * 2018-07-20 2021-06-15 Pf Medicament Receptor for vista.
CN111715409B (en) * 2020-07-01 2021-07-23 中南大学 Combined lead inhibitor of micro-fine particle galena and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025808A1 (en) * 1998-10-30 2000-05-11 Genetics Institute, Inc. Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
WO2001073028A2 (en) * 2000-03-24 2001-10-04 Genetics Institute, Llc A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025808A1 (en) * 1998-10-30 2000-05-11 Genetics Institute, Inc. Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
WO2001073028A2 (en) * 2000-03-24 2001-10-04 Genetics Institute, Llc A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BURDICK M.M. ET AL: "Cell-cell interactions in inflammation and cancer metastasis", IEEE ENG MED BIOL MAG., vol. 20, no. 3, May 2001 (2001-05-01), pages 86 - 91 *
KIM Y.J. ET AL: "P-selectin deficiency attenuates tumor growth and metastasis", PROC NATL ACAD SCI U S A, vol. 95, no. 16, 4 August 1998 (1998-08-04), pages 9325 - 9330 *

Also Published As

Publication number Publication date
MXPA05000272A (en) 2005-09-20
JP2005536199A (en) 2005-12-02
CN1678347A (en) 2005-10-05
WO2004003166A2 (en) 2004-01-08
BR0312483A (en) 2005-08-09
RU2005101621A (en) 2005-11-20
CA2491363A1 (en) 2004-01-08
IL166063A0 (en) 2006-01-15
EP1534332A2 (en) 2005-06-01
AU2003263764A1 (en) 2004-01-19
WO2004003166A3 (en) 2005-03-10
PL374439A1 (en) 2005-10-17
KR20060011925A (en) 2006-02-06

Similar Documents

Publication Publication Date Title
IL225633A0 (en) Anti-alpha-v-beta - 6 antibodies and uses thereof
EP1551447A4 (en) Anti-addl antibodies and uses thereof
HK1248731A1 (en) Immunoglobulin variants and uses thereof
EP1551877A4 (en) Taci antibodies and uses thereof
AU2003299778A8 (en) Antibodies against gpr64 and uses thereof
EP1539941A4 (en) Adzymes and uses thereof
EP1494693A4 (en) Cripto-specific antibodies
IL172871A0 (en) Rg1 antibodies and uses thereof
PL375405A1 (en) Antibodies
EP1699485A4 (en) Anti-hydroxylase antibodies and uses thereof
IL172510A0 (en) Antibodies and uses thereof
IL166063A0 (en) Antibodies and uses thereof
EP1589033A4 (en) Antibody and use thereof
AU2003231827A8 (en) Pseudo-tissues and uses thereof
AU2003249533A8 (en) Neoplasm specific antibodies and uses thereof
AU2003298739A8 (en) Intermedin and its uses
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
GB0226878D0 (en) Antibodies
AU2003216442A8 (en) Enkurin and uses thereof
EP1627888A4 (en) Antibody and use thereof
GB0227080D0 (en) Antibodies and uses thereof
AU2003228397A8 (en) Hausp-p53 interaction and uses thereof
AU2003270518A8 (en) Therapeutic anti-bgp(c-cam1) antibodies and uses thereof
EP1557430A4 (en) Antibody and utilization of the same
AU2003263751A8 (en) Novel proteins and their uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050118

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20061024

17Q First examination report despatched

Effective date: 20070419

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070830